Prior BCG vaccination improves survival of gambian patients treated for pulmonary tuberculosis

Tropical Medicine and International Health

Volumn 5, Issue 6, 2000, Pages 413-417

  Corrah, Tumani ^a   Byass, Peter ^a   Jaffar, Shabbar ^d   Thomas, Vi ^a   Bouchier, V ^b   Stanford, John L ^c   Whittle, Hilton C ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b Ministry of Health   (Gambia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MRC Laboratories Fajara ^*

Author keywords

Bc; Pulmonary tuberculosis; The Gambia

Indexed keywords

BCG VACCINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

DISEASE CONTROL; SURVIVAL; TUBERCULOSIS; VACCINATION;

ADOLESCENT; ADULT; AGE; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; EDEMA; FEMALE; GAMBIA; HUMAN; IMMUNOPROPHYLAXIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; SKIN SCAR; SURVIVAL; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BCG VACCINE; FEMALE; GAMBIA; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TUBERCULOSIS, PULMONARY;

GAMBIA;

ACTINOBACTERIA (CLASS); MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; UNCULTURED ACTINOMYCETE;

EID: 0033925713     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2000.00571.x     Document Type: Article

References (13)

1. Beskow R et al. (1980) Tuberculin sensitivity in Swedish school-children vaccinated with BCG at birth. Bulletin of the International Union Against Tuberculosis 55, 100-104.
2. Bloom BR & Fine PEM (1994) The BCG experience: implications for future vaccines against tuberculosis. In: Tuberculosis: Pathogenesis, Protection and Control (ed. BR Bloom) American Society of Microbiology, Washington DC, pp. 531-557.
3. Colditz GA, Berkey CS, Mosteller F et al. (1995) The efficacy of Bacillus Calmette-Guerin Vaccination of new-borns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Paediatrics 96, 29-35.
4. Fine PEM (1988) BCG vaccination against tuberculosis and leprosy. British Medical Bulletin 44, 691-703.
5. Fine PEM (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339-1345.
6. Fine PEM, Ponnighaus JM & Maine N (1989) The distribtition and implications of BCG scars in northern Malawi. Bulletin of the World Health Organization 67, 35-42.
7. Karonga Prevention Trial Group (1996) Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for the prevention of leprosy and tuberculosis in Malawi. Lancet 348, 17-24.
8. Nunn P, Brindle R & Carpenter L (1992) Cohort study of Human Immunodeficiency Virus infection in patients with tuberculosis in Nairobi, Kenya. American Review of Respiratory Disease 146, 649-654.
9. Ottenhof TH, Kumararatne D & Casanova JL, (1998) Novel human immunodeficiencies reveal the role of type-1 cytokines in immunity to intracellular bacteria. Immunology Today 19, 491.
10. Pyakalia T & Pust R (1977) BCG scar surveys in Enga province: a medical anthropology note. Papua New Guinea Medical Journal 20, 141-142.
11. Ravn P, Boesen B, Pedersen K & Andersen P (1997) Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guerin. Journal of Immunology 158, 1949.
12. Rodrigues LC, Diwan VK & Wheeler JG (1993) Protective effect of BCG against tuberculosis, meningitis and miliary tuberculosis: a meta-analysis. International Journal of Epidemiology 22, 1154-1158.
13. Tuberculosis Prevention Trial Madras (1980) Trial of BCG vaccines in south India for tuberculosis prevention. Indian Journal of Medical Research 72 (Suppl.), S1-S74.